Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII.
Thrombelastgram (TEG) is an old but automated instrument that demonstrates changes occurring during blood coagulation and fibrinolysis. TEG was evaluated to be better than activated partial thromboplastin time (APTT) as a monitor of hemostatic effects when using recombinant factor VIIa (65-80 mu g/kg) in 3 hemophilia A patients with a high titer of factor VIII inhibitors. TEG was more suitable than APTT, because r, r + k and ma values of TEG were normalized at least for 4 h after the infusion, whereas APTT was variably shortened and was not always maintained at a normal level for 4 h.
Department of Pediatrics, Nara Medical University, Japan.
A
A
Yoshioka
K
K
Nishio
M
M
Shima
D000328:Adult; D001331:Automation; D001777:Blood Coagulation / Q000187:drug effects; D005069:Evaluation Studies as Topic; D005169:Factor VIII / Q000037:antagonists & inhibitors* / Q000276:immunology; D015942:Factor VIIa / Q000627:therapeutic use*; D005342:Fibrinolysis / Q000187:drug effects; D006467:Hemophilia A / Q000188:drug therapy*; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D013916:Thrombelastography; D016896:Treatment Outcome
D011994:Recombinant Proteins; D005169:Factor VIII; D015942:Factor VIIa